| Molecular formula | C228H388N86O64 |
|---|
| Molecular weight | 5358 g/mol |
|---|
| Registered trials | 0 |
|---|
| PubChem CID | 167312269 |
|---|
What FOXO4-DRI Is
FOXO4-DRI is a synthetic peptide studied only in laboratory and research settings. It has no FDA-approved label, no approved indications, and no approved brand name. The compound is a large peptide, with a molecular formula of C228H388N86O64 and a molecular weight near 5,358, and it is catalogued under PubChem CID 167312269. Because no regulatory label exists for this compound, no mechanism, indication, or dosing information can be sourced from an official label.
Trial Footprint
Public trial registries show zero registered clinical trials for FOXO4-DRI at this time. No trial records, phases, or study results are available to summarize. This reflects the compound's current standing as an unapproved research substance rather than a clinically studied drug candidate.
FAQ
No. FOXO4-DRI has no FDA-approved label, no approved brand name, and no approved medical use. It is classified as an unapproved research compound.
Public registries currently list zero registered clinical trials for FOXO4-DRI. There is no available trial data on its phase, design, or outcomes.
FOXO4-DRI is a large synthetic peptide with the molecular formula C228H388N86O64 and a molecular weight of approximately 5,358. It is indexed in PubChem under CID 167312269.
No adverse event reports or side effect data are currently available for FOXO4-DRI. This is consistent with its status as a compound that has not entered registered clinical trials.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 167312269 ClinicalTrials.gov registry search
Updated 2026-09-19